In the high-stakes environment of an intensive care unit or an emergency department, clinicians must make critical decisions in seconds. Among the most frequent and challenging of these decisions is determining exactly how much intravenous fluid to give a critically ill patient. Intravenous fluids are the frontline treatment for severe conditions like sepsis, but managing them is a delicate balancing act. Giving too little fluid can cause organ failure due to inadequate blood flow, while giving too much can flood the lungs, cause heart congestion, and increase patient mortality.
Historically, tracking how a patient’s circulatory system responds to fluids in real time has required invasive procedures, bulky machines, or highly specialized training. This gap in bedside monitoring has left medical teams facing a difficult challenge.
Flosonics Medical, a pioneer in wearable healthcare technology, has changed this paradigm. Under the leadership of CEO and Co-Founder Dr. Joe Eibl, the company developed FloPatch, the world’s first wireless, wearable Doppler ultrasound device. By sticking a smart sensor to a patient’s neck, healthcare providers can now see blood flow changes continuously and non-invasively. This shift from manual, intermittent checks to automated, continuous monitoring is reshaping critical care.
The Bedside Challenge of Fluid Management
To understand the impact of this innovation, it is essential to look at the clinical problem it solves. Sepsis, an extreme and life-threatening response to an infection, affects millions of people globally every year. When a patient goes into septic shock, their blood pressure drops drastically because of an intense systemic inflammatory response. To counter this, emergency protocols traditionally mandate rapid and aggressive intravenous fluid resuscitation. The goal is to boost the volume of blood returning to the heart, thereby restoring stable blood pressure and oxygen delivery to vital organs.
However, clinical research shows that nearly one-third of patients with septic shock do not respond positively to additional intravenous fluids after the initial rescue doses. For these fluid-nonresponsive patients, extra volume does not increase cardiac output. Instead, the excess fluid leaks into the surrounding tissues and organs. The lungs become congested with water, making breathing difficult and often forcing clinicians to place the patient on a mechanical ventilator. The heart becomes overworked and congested, and the kidneys can fail, requiring acute dialysis.
Despite these clear dangers, frontline medical teams have historically lacked the tools needed to evaluate fluid responsiveness quickly and accurately at the bedside. Traditional assessment methods fall into two categories, both of which have major limitations:
- Invasive Monitoring: Tools like central venous catheters or arterial lines require inserting tubes directly into a patient’s blood vessels. While they provide detailed data, these procedures carry risks of infection, bleeding, and vascular damage. They take time to set up and are generally restricted to intensive care units, making them impractical for rapid assessment in emergency rooms or ambulances.
- Traditional Ultrasound: Point-of-care ultrasound is highly effective but demands significant expertise. A trained physician must manually hold a bulky probe against the patient’s neck or chest to measure blood flow through major vessels. This approach only provides a single snapshot in time. The moment the doctor removes the probe, the continuous stream of data stops. Because emergency rooms and intensive care units are fast-paced and understaffed, keeping a specialist at a single bedside to hold an ultrasound probe for hours is impossible.
As a result, clinical teams have often been forced to rely on indirect and slow-moving signs, such as blood pressure trends or urine output, to guess whether a patient needs more fluid. This lack of precise, real-time data created a critical need for a tool that could deliver accurate, continuous hemodynamic data without requiring a specialist to remain at the bedside.
The Scientist at the Helm
Dr. Joe Eibl brought a strong scientific background to this clinical challenge. He holds a PhD in Biomolecular Sciences and completed advanced postdoctoral training in bioengineering. This academic background gave him a deep understanding of cellular mechanics, material sciences, and electronic systems. Rather than remaining within academic research, Dr. Eibl focused on translating complex laboratory discoveries into practical medical technologies that could solve real-world problems.
As the CEO and Co-Founder of Flosonics Medical, Dr. Eibl is responsible for directing the company’s growth, developing its core technology, managing its intellectual property portfolio, and setting its business strategy. His scientific background allows him to bridge the gap between technical engineering teams and clinical medical professionals. He understands both the engineering challenges of building miniature ultrasound sensors and the rigorous data demands of the regulatory bodies that approve new medical devices.
A Personal Crisis Sparks an Innovation
Great medical innovations often stem from personal experiences, and Flosonics Medical is no exception. The company’s foundation dates back to the early 2000s at the University of British Columbia. On his first day of university, Joe Eibl met his freshman roommate, Jon Emile Kenny. The two became close friends and followed parallel paths in science and healthcare. While Eibl pursued a career in biomolecular science and bioengineering research, Kenny went into medicine, training at the University of Toronto, New York University, and Stanford University to become a critical care physician.
Years later, a sudden family crisis brought their separate paths together. Dr. Eibl’s father suffered a severe heart attack. While he survived the initial event and underwent successful open-heart surgery, his recovery was severely compromised when he developed hospital-acquired sepsis.
During his treatment, Dr. Eibl’s father became critically ill and spent three weeks in the hospital. In an effort to stabilize his crashing blood pressure, medical teams administered a massive volume of intravenous fluids totaling 16 liters during the early stages of his resuscitation. This aggressive fluid therapy caused severe systemic swelling. His body became congested with excess fluid, his lungs struggled to function, and he faced severe complications before finally recovering.
Watching his father suffer from the side effects of fluid overload, Dr. Eibl called Dr. Kenny to understand why the treatment was causing such visible harm. Dr. Kenny explained that fluid overload was an incredibly common, complex, and frustrating challenge faced by ICU doctors every day. He noted that clinicians knew excessive fluid was harmful, but they simply did not have an easy, continuous way to measure blood flow at the bedside to determine when to stop the intravenous lines.
This conversation served as a turning point. Dr. Eibl realized that his expertise in bioengineering, combined with Dr. Kenny’s frontline clinical experience in critical care, could solve this problem. They decided to build a device that could give doctors an objective, real-time view of a patient’s fluid status.
Turning an Ultrasound Machine into a Wearable Patch
In 2015, Dr. Joe Eibl, Dr. Jon Emile Kenny, and Andrew Eibl co-founded Flosonics Medical in Sudbury, Ontario, Canada. Their goal was highly ambitious: take a traditional, cart-based ultrasound machine, which weighs hundreds of pounds and costs tens of thousands of dollars, and shrink its core Doppler capabilities into a small, affordable, wireless patch that sticks to a patient’s neck.
The team focused on the carotid artery, the primary blood vessel in the neck that carries blood from the heart to the brain. Because the carotid artery sits close to the surface of the skin, it provides an excellent anatomical window to observe how blood exits the left side of the heart. By measuring the changes in blood flow velocity within the carotid artery as a patient’s position changes or as fluids are introduced, doctors can determine if the heart has the capacity to pump more blood when given more fluid.
To achieve this, the engineering team had to solve several major technical challenges:
- Miniaturization: They needed to design ultra-thin piezoelectric crystals capable of emitting and receiving high-frequency ultrasound waves while powered by a tiny, lightweight battery.
- The Ultrasound Curtain: Traditional ultrasound requires an operator to precisely angle a probe to capture a thin slice of a blood vessel. If the patient moves even slightly, the vessel slips out of view. Flosonics solved this by developing a wide ultrasound curtain roughly 2.5 centimeters across. This beam is deep and wide enough to span the neck, ensuring that it continuously captures blood flow through both the carotid artery and the jugular vein, even if the patient moves or has a thick neck.
- Wireless Data Transmission: The sensor needed to process complex acoustic data instantly and transmit it via Bluetooth to a smartphone or tablet running the Flosonics application. This allows any nurse or doctor to view real-time, high-fidelity hemodynamic data on an iPad or iPhone right at the bedside.
The resulting product was named the FloPatch. Shaped like a large bandage, the single-use, sterile device adheres to the side of a patient’s neck. Once activated, it automatically locates the blood vessels and begins broadcasting blood flow analytics to the clinical team’s mobile devices, providing an immediate, clear picture of the patient’s circulatory response.
Overcoming Regulatory Hurdles and Scaling Up
Introducing an entirely new category of medical hardware to the healthcare industry is an expensive and highly regulated process. As a first-time founder, Dr. Eibl had to guide Flosonics Medical through strict clinical trials, manufacturing audits, and fundraising rounds.
The company secured early venture capital backing from healthcare-focused investors, including iGan Partners, Genesys Capital, and Arboretum Ventures. These partnerships provided the financial foundation and regulatory guidance needed to transition FloPatch from a working prototype into a commercial medical device.
Flosonics focused heavily on generating strong clinical evidence to prove that the device was accurate, safe, and easy for frontline nurses to use. This commitment to research paid off, allowing the company to secure key regulatory milestones, including Health Canada clearance, a European CE Mark, and clearance from the United States Food and Drug Administration (FDA).
With regulatory approvals in hand, Dr. Eibl shifted the company’s focus toward large-scale commercial adoption. In March 2024, Flosonics Medical secured 20 million USD in Series C funding. This round was led by New Leaf Venture Partners, a top healthcare technology venture firm, with continued participation from its early investors. Following this momentum, on March 3, 2025, Flosonics secured an additional 7.5 million CAD (5.5 million USD) in venture debt financing from RBCx, the technology banking arm of the Royal Bank of Canada. This capital injection enabled the company to expand its manufacturing capabilities, fund further clinical studies, and accelerate its commercial expansion across North American hospitals.
By late 2025 and into 2026, the technology achieved significant coast-to-coast market traction. On June 17, 2025, the prestigious Mount Sinai Hospital in New York formally adopted FloPatch into its surgical and transplant intensive care units, establishing the company’s first major East Coast clinical deployment. Meanwhile, large integrated healthcare networks on the West Coast, such as Sutter Health in Northern California, expanded their deployment of FloPatch across multiple hospital campuses to advance their sepsis care. To date, the FloPatch has been used to guide the care of thousands of critically ill patients across North America.
Shifting the Paradigm with Wearable AI Sensors
Dr. Eibl’s long-term vision for Flosonics Medical extends beyond providing a convenient alternative to traditional ultrasound probes. He envisions a fundamental shift toward data-driven, predictive critical care enabled by wearable artificial intelligence.
The traditional healthcare model relies on periodic, manual assessments such as checking a patient’s vitals every few hours. Dr. Eibl points out that a patient’s hemodynamic status can change completely in a matter of minutes. By utilizing a wearable sensor like the FloPatch, medical teams gain access to a continuous stream of physiological data that was previously impossible to collect.
To make this massive volume of data actionable for busy hospital staff, Flosonics integrates advanced AI algorithms into its software platform. The live Doppler spectrogram view on the FloPatch app automatically analyzes blood velocity patterns, filters out movement artifacts, and calculates exact clinical metrics, specifically Corrected Flow Time ($FT_c$) and Velocity Time Integral ($VTI$). Instead of forcing a nurse or doctor to interpret raw, complex ultrasound waves, the system provides clear, objective data indicating fluid responsiveness. This democratization of data allows any trained healthcare provider, regardless of whether they have advanced training in sonography, to perform high-level hemodynamic assessments in minutes.
This approach is highly scalable across entire healthcare organizations. It allows emergency departments, operating rooms, intensive care units, and even rural ambulances to use the exact same objective data standards. This helps hospitals comply with strict institutional guidelines, such as the Centers for Medicare & Medicaid Services (CMS) SEP 1 sepsis treatment mandates, which require timely and well-documented fluid management decisions.
Leading with Intellectual Rigor and Open Collaboration
Dr. Joe Eibl’s approach to leadership reflects his dual background as a research scientist and an entrepreneur. He balances a strong focus on technical and intellectual property development with an open, collaborative management style. He recognizes that building a disruptive medical device company requires a diverse team of experts, including software engineers, hardware designers, clinical researchers, and regulatory specialists.
Rather than adopting a rigid, top-down hierarchy, Dr. Eibl cultivates an environment focused on evidence-based problem-solving. Every design iteration, business pivot, and marketing strategy is driven by data, user feedback from clinical settings, and scientific validation.
This emphasis on rigorous data also guides how Flosonics interacts with the wider medical community. Under Dr. Eibl’s leadership, the company does not just sell hardware; it actively collaborates with leading academic institutions and clinical researchers to publish peer-reviewed studies. A notable example is the development and publication of the Safe and Fluid Effective Resuscitation (SaFER) protocol in SN Comprehensive Clinical Medicine on March 17, 2026. Co-authored by Flosonics co-founder and CMO Dr. Jon Emile Kenny and Stanford University’s Dr. Carolyn Kaufman, this protocol provides medical teams with a clear, standardized bedside framework to guide intravenous fluid decisions using wireless Doppler technology. By backing its technology with transparent, peer-reviewed clinical research, Dr. Eibl has built deep trust with conservative medical institutions and hospital leadership groups.
Transforming Sepsis Care on a National Scale
The future looks highly promising for both Dr. Joe Eibl and Flosonics Medical. The company’s steady commercial momentum was highlighted on March 3, 2026, when Flosonics announced that the FloPatch had received an Innovative Technology contract from Vizient, Inc. Vizient is the largest provider-driven healthcare performance improvement company in the United States, managing a diverse client base that includes academic medical centers, community hospitals, and pediatric facilities representing more than 156 billion USD in annual purchasing volume.
This contract serves as a major endorsement of the FloPatch. Vizient awards Innovative Technology contracts only after comprehensive reviews by client-led clinical councils, which evaluate products for their potential to bring meaningful innovation to healthcare delivery. Through this agreement, thousands of hospitals across the United States gain direct, streamlined access to the FloPatch, allowing them to scale and standardize their sepsis care protocols more effectively.
Looking ahead, Flosonics Medical is well positioned to expand its technology beyond fluid management in sepsis. The underlying platform, a wearable, wireless AI-assisted Doppler sensor, can potentially be applied to a wide range of clinical scenarios where real-time blood flow monitoring is vital. This includes tracking cardiac function in patients with chronic heart failure, monitoring surgical patients during recovery, and assisting emergency paramedics in the field.
By focusing on a clear clinical need, maintaining a strong commitment to rigorous scientific research, and keeping a steady focus on user-friendly design, Dr. Joe Eibl has successfully guided Flosonics Medical from an innovative idea born of a personal family crisis into a commercially successful medtech leader. As wearable sensors and artificial intelligence become deeply integrated into modern hospital networks, Flosonics Medical stands at the forefront, providing frontline healthcare workers with the real-time data they need to make life-saving decisions at the bedside.
